Take-home message {#FPar1}
=================

Eighteen percent of patients in the EUROMACS registry died within 90-days following LVAD implantation.Early mortality after LVAD implantation is primarily dominated by multiorgan failure followed by sepsis.A simple model of 12 variables predicts early mortality following LVAD implantation with a good discriminative power with area under the curve of 0.75.

Introduction {#Sec1}
============

Continuous-flow left ventricular assist devices (LVADs) are increasingly used for treating patients with end-stage heart failure as a bridge to cardiac transplantation (HTx) or as a destination therapy (DT). Compared with medical therapy, LVAD implantation has reduced death and improved quality of life \[[@CR1]--[@CR3]\]. Current state-of-the-art devices are promising in terms of improved survival and lower morbidity rates \[[@CR4]\]. However, early post-LVAD mortality remains high \[[@CR5]--[@CR8]\]. Furthermore, causes and determinants of death following LVAD implantation are not well described for the European population. In small series, high post-LVAD mortality is associated with acute kidney injury (AKI) and multi-organ failure \[[@CR9], [@CR10]\]. There are few data on predictors of early ICU death (≤ 90 days) after LVAD implantation \[[@CR11]\].

Therefore, we aimed to investigate the causes of death early after LVAD implantation. Furthermore, we sought to explore predictors of early death using multivariate analysis. The preliminary result of this study is partly presented at the scientific sessions of the European Society of Cardiology Congress \[[@CR12]\].

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

All consecutive patients treated with mainstream continuous-flow LVAD devices (i.e., HeartMate II, HeartWare, and HeartMate 3) from EUROMACS, a Registry of the European Association for Cardio-Thoracic Surgery, from January 2006 until May 2017 were included. All participating hospitals sign a contract with the EUROMACS Registry. In the contract, it is agreed that patients are sufficiently informed about the treatment that they are to undergo, including the risk of complications and mortality. The Registry contains data for scientific analyses, and is aimed at improving care of patients with end-stage heart failure (HF) who need mechanical circulatory support \[[@CR13]\]. All relevant clinical, echocardiographic, hemodynamic, and laboratory characteristics were prospectively collected by participating EUROMACS sites and entered into an electronic database (see appendix Table 1 for the list of EUROMACS sites and investigators (alphabetical according to country). To ensure the best quality of data and to exclude the underreporting of poor outcomes, the EUROMACS Registry applies several methods. Incoming data are analyzed on a regular basis. Individual hospitals are approached, and guidance is offered to complete or correct their data. Entries are adapted to adhere to the standard. Twice a year, each center receives a file in which an overview of patients whose statuses need to be updated and whose changes/answers have to be monitored is presented. Statistical consistency and plausibility checks are performed, and the records containing the inconsistent data of the participating centers are identified. Data that are not plausible require checking and confirmation by the participating centers. Details of the Registry and data collection are described elsewhere \[[@CR13]\]. This study was approved by the local institutional review committee and all subjects provided informed consent.

Study outcome {#Sec4}
-------------

We defined early mortality as death within 90 days after LVAD implantation. The EUROMACS registry protocol mandates sites to report death using a list of 17 causes of death as follows: multi-organ failure (MOF), cerebro-vascular accident (CVA), sepsis, infection, bleeding, cardiopulmonary failure (CPF), right-sided heart failure (RHF), device failure, lung failure, myocardial infarction, suicide, cancer, left heart failure, pulmonary artery embolism, trauma, other causes of death, and unknown cause of death. MOF implies usually two or more organs' dysfunction at the same time. We combined sepsis and infection into sepsis as main cause of death. Similarly, cardiopulmonary failure, left heart failure, lung failure, pulmonary artery embolization, and myocardial infarction into cardiopulmonary failure (CPF). Right-sided heart failure (RHF) as directly related to death was documented independently, when RHF does not lead to MOF or sepsis \[[@CR14], [@CR15]\]. Therefore, we created eight dominant causes of death including sepsis, MOF, CVA, CPF, bleeding, RHF, device failure, and others. Other causes of death included cancer, suicide, trauma, and all other than main causes of death.

Potential predictors of early mortality {#Sec5}
---------------------------------------

We examined potential pre-operative characteristics as well as surgical and cardiopulmonary bypass (CPB) time for the association with early mortality. Pre-operative clinical data included age, gender, body surface area, body mass index, and blood type, HF etiology, NYHA functional profile, and INTERMACS profile were taken into account \[[@CR16]\]. The pre-operative use of ≥ 3 intravenous inotropes as well as the use of vasopressors were included. Furthermore, LVAD device strategy such as DT, use of intra-aortic balloon pump (IABP), and extracorporeal membrane oxygenator (ECMO) were additionally included. Pre-operative echocardiographic characteristics were recorded and analyzed in accordance with published guidelines \[[@CR17], [@CR18]\] including tricuspid annular plane systolic excursion (TAPSE), RV dysfunction on visual score, LV ejection fraction (LVEF), and mitral, aortic, and tricuspid valvular regurgitation. Median duration of echocardiographic data collection before LVAD surgery was 6 days. Severity of valvular regurgitation was graded as none, trivial, mild, moderate, and severe according to published guidelines \[[@CR19], [@CR20]\].

Hemodynamic predictors included heart rate, systolic and diastolic blood pressure, as well as Swan-Ganz recordings. The latter included systolic, diastolic and mean pulmonary artery (PA) pressure, right atrial (RA) pressure, pulmonary capillary wedge pressure (PCWP), pulmonary (PVR) and systemic (SVR) vascular resistance, and cardiac index. The PVR is calculated as transpulmonary gradient (TPG) divided by the cardiac output (CO), which has a normal value of \< 3 Wood units (or 240 dynes·sec·cm^−5^). TPG was calculated as the difference between the PA mean pressure and PCWP. The ratio of RA to PCWP and PA pulsatility index (PAPi) \[[@CR21]\] were also calculated. The RV systolic work index (RVSWI) was calculated as RV stroke volume index × (mean PA pressure − central venous pressure) × 0.0136 expressed in gm/m^2^/beat were calculated. The factor 0.0136 was used to covert pressure (mmHg) into work (g/m^2^). Normal values are 5--10 g/m^2^/beat.

Laboratory characteristics included serum sodium and potassium levels, renal function parameters including blood urea nitrogen, serum creatinine levels, and liver function parameters including AST, LDH, total bilirubin, and serum albumin level. In addition, white blood count, platelets count, INR, APTT, lactate, and hemoglobin levels were also included.

Statistical analysis {#Sec6}
--------------------

Patient characteristics are described as means (standard deviation \[SD\]) or medians (interquartile range \[IQR\]) for continuous variables and frequency (percentage) for categorical variables. Differences between patient groups are evaluated for continuous variables by the Student *t*tests (Gaussian distribution) or the non-parametric Mann--Whitney *U*tests (non-Gaussian distribution) and the categorical variables using the Chi-square test.

Univariate logistic regression analysis was applied to relate a broad range of pre-operative parameters with the study outcome, including demographics, clinical, medications, echocardiographic, hemodynamic, and laboratory characteristics. Variables with a *p*value \< 0.20 entered the multivariate stage, and a multivariate regression model was constructed to predict early mortality following LVAD implantation, applying the stepwise forward method, with a *p* = 0.05 model-entry criterion.

For the main causes of death, we calculated and reported the frequencies for early mortality in time-based analysis beginning from the day of implantation till 30 days and between 30 and 90 days. We reported the cumulative early mortality. Multiple imputations were used to account for randomly missing values after examining the pattern of missing values as described before \[[@CR14]\]. We accepted the missing data for \< 20% of in the entire population. The goodness-of-fit of the logistic regression model was measured in terms of its calibration. Calibration, which measures the ability of the model to fit the data, was tested with the Hosmer--Lemeshow statistic.

A two-tailed *p* \< 0.05 was considered statistically significant, and all statistics were undertaken using the SPSS statistics version 24 (IBM corporation, NY, USA), MedCalc (Statistical MedCalc Software, Ostend, Belgium), and the R-statistical package.

Results {#Sec7}
=======

Study cohort {#Sec8}
------------

Between January 1, 2006, and May 31, 2017, a total of 2988 adult patients who underwent continuous-flow LVAD implantation with mainstream devices (HeartWare, HeartMate II, or HeartMate 3) were included. We excluded patients missing data about the brand type of LVAD (*n* = 35) and missing follow-up data (*n* = 264) (Fig. [1](#Fig1){ref-type="fig"}). The final study population comprised 2689 patients with a mean age of 53 ± 13 years and 472 (18%) women (Table [1](#Tab1){ref-type="table"}); the majority were Caucasians (66%, *n* = 1785). The main etiology of HF was non-ischemic (67%, *n* = 1807). The main indications for LVAD implantation were bridge to candidacy (44%, *n* = 1001), followed by BTT (29%, *n* = 655). Mainstream devices were HeartWare® HVAD as the most used LVAD brand (51%, *n *= 1369), followed by HeartMate II® (43%, *n* = 1167) and HeartMate 3® (6%, *n *= 153).Fig. 1Flowchart of the study population. This flowchart describes the outcome in total population of EUROMACS over follow-up of 90 days. *EUROMACS* The European Registry for Patients with Mechanical Circulatory Support, *LVAD* left ventricular assist deviceTable 1Baseline and peri-operative characteristics of patients undergoing continuous-flow LVAD implantationVariablesTotal population (*N* = 2689)Survivors 90 days (*n* = 2202)Non-survivors 90 days (*n* = 487)*p* value***Demographics*** Age, year53 ± 1352 ± 1255 ± 13 \< 0.001 Gender (Female), *n* (%)472 (18)373 (17)99 (20)0.08 Body surface area, m^2^1.96 ± 0.231.96 ± 0.231.96 ± 0.260.66 Body mass index, kg/m^2^26.1 ± 526 ± 4.826.7 ± 5.60.01 Ischemic etiology, *n* (%)882 (33)704 (32)178 (37)0.06 Blood type O, *n* (%)1010 (38)823 (37)187 (38)0.68 INTERMACS class, *n* (%) \< 0.001  1297 (11)182 (8)115 (24)  2854 (32)663 (30)191 (39)  3693 (26)610 (28)83 (17)  ≥ 4737 (27)653 (30)84 (17) IABP, %246 (9)185 (8)61 (13)0.01 VA-ECMO, %249 (9)101 (5)148 (30) \< 0.001 NYHA functional class, *n* (%)0.001  III838 (31)715 (32)123 (25)  IV1110 (41)875 (40)235 (48) Intravenous medication, *n* (%)  Use of vasopressors574 (21)381 (17)193 (40) \< 0.001  Use of inotropes ≥ 3340 (13)243 (11)97 (20) \< 0.001***Laboratory*** Serum creatinine, mg/dL1.17 \[0.96--1.5\]1.15 \[0.95--1.43\]1.29 \[1.06--1.84\] \< 0.001 BUN, mg/dL48 \[34--74\]46 \[32--68\]63 \[40--97\] \< 0.001 AST, U/L31 \[22--64\]30 \[21--53\]46 \[25--187\] \< 0.001 LDH, U/L340 \[257--489\]334 \[252--474\]364 \[271--591\] \< 0.001 Total bilirubin, mg/dL1.32 \[0.83--2.05\]1.27 \[0.8--1.9\]1.64 \[1.1--2.6\] \< 0.001 WBC, 10^9^/mL8.2 \[6.5--10.7\]8 \[6.4--10.3\]9.3 \[6.9--12.6\] \< 0.001 Platelets, 1000/mL207 \[158--252\]211 \[170--254\]179 \[116--240\] \< 0.001 INR1.3 \[1.1--1.6\]1.24 \[1.1--1.5\]1.39 \[1.2--1.8\] \< 0.001 aPTT, sec39 \[32--47\]39 \[32--46\]42 \[34--53\] \< 0.001 Lactate, mmol/L1.5 \[1.1--2.3\]1.4 \[1--2.1\]1.6 \[1.1--3.5\] \< 0.001 Albumin, mg/dL3.9 \[3.3--5.2\]3.9 \[3.4--5.2\]3.6 \[3.2--4.7\] \< 0.001 Hemoglobin, g/dL12.1 \[10.5--13.9\]12.4 \[10.8--14\]10.9 \[9.8--12.7\] \< 0.001***Hemodynamic*** Heart rate, beats/min85 \[74--98\]84 \[74--98\]88 \[75--101\]0.01 Diastolic BP, mmHg65 \[59--71\]65 \[60--72\]62 \[55--70\]0.07 Systolic BP, mmHg100 \[90--110\]100 \[90--110\]100 \[88--110\]0.07 RA pressure, mmHg11 \[8--15\]10 \[7--14\]13 \[9--17\] \< 0.001 PCWP, mmHg24 \[18--29\]24 \[29\]25 \[29\]0.32 PAP systolic52 \[41--63\]53 \[41--63\]52 \[40--62\]0.37 PAP diastolic26 \[20--32\]26 \[20--32\]26 \[21--32\]0.72 PAP mean, mmHg35 \[28 -- 42\]35 \[28--42\]35 \[27--42\]0.82 CO, L/min3.6 \[3.0--4.4\]3.6 \[2.9--4.4\]3.6 \[2.9--4.4\]0.08 CI, L/min/m^2^1.9 \[1.5--2.2\]1.9 \[1.5--2.2\]1.9 \[1.6--2.3\]0.07 RVSWI, g/m^2^/beat6.7 \[5.1 -- 9.3\]6.3 \[4.6--8.9\]6.9 \[5.2-- 9.4\] \< 0.001 SVR, Woods units18.2 \[14.2--23\]17.9 \[13.6--23.4\]15.7 \[11.9--20.3\] \< 0.001 PVR, Woods units2.9 \[1.6---4.8\]3.2 \[2.1--4.5\]3.3 \[2--4.7\]0.08 RA/PCWP0.46 \[0.33--0.65\]0.45 \[0.32--0.63\]0.52 \[0.38--0.75\] \< 0.001 PAPi2.4 \[1.54--3.69\]2.5 \[1.62--3.89\]2 \[1.33--3.1\] \< 0.001***Echocardiographic*** Severe RV dysfunction, *n* (%)257 (10)179 (8)78 (16) \< 0.001 TAPSE, mm/s14 \[5--30\]14 \[5--30\]14 \[7--29\]0.48 Moderate-to-severe tricuspid regurgitation, *n* (%)271 (10)534 (36)388 (41)0.93 Moderate-to-severe mitral regurgitation, *n* (%)36 (2)674 (56)377 (44)0.51 Moderate-to-severe aortic regurgitation, *n* (%)128 (6)45 (4)40 (5)0.001 LV-EF grade \< 20%, *n* (%)1045 (53)831 (38)214 (44)0.19 Main LVAD strategy \< 0.001  BTT (on the list)655 (29)462 (35)193 (20)  BTC1001 (44)573 (44)428 (45)  Destination therapy441 (19)187 (14)254 (27)  Rescue therapy130 (6)65 (5)65 (7)  BTR and others44 (2)25 (2)19 (2) LVAD device brand, *n* (%)  HeartMate II1167 (43)1033 (47)134 (28) \< 0.001  HeartMate 3153 (6)112 (5)41 (8) \< 0.001  Heart Ware HVAD1369 (51)1057 (48)312 (64)0.007 Surgical duration  CPB time, min86 \[65--15\]86 \[64--113\]91 \[61--133\] \< 0.001  Surgery time, min230 \[180--285\]225 \[180--277\]255 \[193--330\] \< 0.001All continuous values are presented in mean ± standard deviation unless stated otherwise or presented as median \[IQR\]. Categorical variables are stated as frequencies and percentages.*AST* serum aspartate transaminase, *IABP* intra-aortic balloon pump, *INTERMACS* the Interagency Registry for Mechanically Assisted Circulatory Support (For INTERMACS classes. see text for details), *LV* left ventricular, *EF* ejection fraction, *LVAD* left ventricular assist device, *VA-ECMO* veno-arterial extracorporeal membrane oxygenator, *NYHA* New York Heart Association, *PAP* pulmonary artery pressure, *PAPi* pulmonary artery pulsatility index, *PCWP* pulmonary capillary wedge pressure, *PVR* pulmonary vascular resistance, *RA* right atrial, *RV* right ventricular, *RVSWI* right-ventricular stroke work index, *TAPSE* tricuspid annular plane systolic excursion, *BTT* bridge to transplant, *BTC* bridge to candidacy, *BTR* bridge to recovery, *CPB* cardio pulmonary bypass

Post LVAD outcome {#Sec9}
-----------------

During follow-up duration of 90 days, out of 2689 patients, 487 (18%) were deceased; 40(2%) were transplanted; in 2 (0.1%), the device was explanted; and 2160 (80%) were alive on LVAD support (Fig. [1](#Fig1){ref-type="fig"}). Differences in key baseline and peri-operative characteristics between survivors and non-survivors are shown (Table [1](#Tab1){ref-type="table"}).

Time course of death after LVAD implantation {#Sec10}
--------------------------------------------

Overall, primary causes of death were sepsis (28%), MOF (26%), and CVA (15%). Furthermore, MOF (36%), sepsis (28%), and CPF (10%) were the main primary causes of death followed by CVA (9%) and RHF (8%) in the early (≤ 90 days) after LVAD implantation (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Detailed time-based presentation of causes of death within 90 days following LVAD implantation in the EUROMACS registry. For abbreviations, see Fig. [1](#Fig1){ref-type="fig"}

Differential causes of death within 90 days following LVAD implantation {#Sec11}
-----------------------------------------------------------------------

In-depth daily or weekly analysis of the differential causes of death in the early 90 days following LVAD implantation revealed MOF as the main cause of death in 40--50% the first 2 weeks and decreased to approximately 10% of total causes of death thereafter. In contrast sepsis is seen in day one as 10% of causes of death, increased to 20--40% thereafter. CPF occurred in 20% at the day of LVAD implantation and decreased to 5% or less thereafter. CVA was seen as 20% of causes of death on the day of LVAD implantation, 5--10% between day 1 to 90 days. Bleeding as a cause of death was seen in 20% of causes of death during day one after LVAD implantation, \< 5% between day 2 and 90 days. RHF as a cause of death was seen in approximately 20% of causes of death during day 1 after LVAD implantation. Device failure was not seen as a cause of death in the first 90 days.

As seen on Fig. [2](#Fig2){ref-type="fig"}, only nine subjects in the study died on the day of operation and 16 subjects died in the first day after the operation. Known causes of death on the operation day were cerebro-vascular accident in one patient, multi-organ failure in two, cardiopulmonary failure in one, and other cause of death in one patient,

In the day after LVAD implantation, known causes of death were MOF in eight patients, RHF in three, bleeding in three, CVA in one, and sepsis in one were seen.

Predictors of early mortality post-LVAD {#Sec12}
---------------------------------------

Univariate exploratory analysis as well as multivariable model of the independent predictor of early mortality following LVAD implantation are seen in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Exploratory univariate logistic regression analysis for early mortality following LVAD implantation yielded 49 potential covariates (*p* \< 0,20) out of 59 tested variables, as clinical, medication, laboratory, echocardiographic, hemodynamic, and operative covariates (Table [2](#Tab2){ref-type="table"}). Independent clinical predictors of early death were age (OR 1.028, 95% CI 1.018--1.038) female sex (OR 1.339, 95% CI 1.003--1.788), INTERMACS profile 1 to 3 (OR 1.500, 95% CI 1.121--2.007), and ECMO (OR 1.989, 95% CI 1.431--2.765). Laboratory predictors included elevated serum creatinine (OR 1.003, 95% CI 1.002--1.005), total bilirubin (OR 1.193, 95% CI 1.116--1.275), lactate (OR 1.011, 95% CI 1.003--1.019), and low hemoglobin (OR 0.908, 95% CI 0.858--0.961). Furthermore, hemodynamic predictors included elevated RA-to-PCWP ratio (OR 1.740, 95% CI 1.292--2.344), pulmonary vascular resistance (OR 1.089, 95% CI 1.044--1.135), and low systemic vascular resistance (OR 0.974, 95% CI 0.957--0.992). Longer total implantation time (OR 1.003, 95% CI 1.002--1.004) was also independent predictor of early mortality (Table [3](#Tab3){ref-type="table"}).Table 2Baseline univariate predictors of early mortality after LVAD implantation using continuous valuesVariablesCoefficient of regressionS.EWald*p* valueORLower 95.0% CI for OR LowerUpper 95.0% CI for OR Upper***Demographics*** Age, year0.0230.00429 \< 0.0011.0231.0151.032 Gender (female)0.2240.12630.0761.2510.9771.602 Body surface area, m^2^− 0.1010.2280.1970.6570.9040.5781.414 Body mass index, kg/m^2^0.0060.0060.8440.3581.0060.9941.017 Race (Caucasian)0.4610.11316.657 \< 0.0011.5851.2711.978 Ischemic aetiology0.2040.1053.7860.0521.2260.9991.505 Blood type O (reference)0.2021---- Blood type A0.0470.1110.1770.6741.0480.8441.301 Blood type AB− 0.2120.2320.8330.3610.8090.5131.275 Blood type B− 0.2700.1662.6580.1030.7630.5511.056 INTERMACS class (1--3 vs 4--7)0.7320.12932.06 \< 0.0012.0781.6132.677 IABP (yes vs no)0.3740.1585.5810.0181.4541.0661.984 VA-ECMO (yes or no)1.2910.14184.176 \< 0.0013.6352.7594.790 Use of vasopressors1.0820.11391.937 \< 0.0012.9502.3653.680 Use of inotropes ≥ 30.60.13419.891 \< 0.0011.8211.3992.371***Laboratory*** Serum creatinine, mol/L0.0060.00161.4810.0001.0061.0051.008 BUN, mg/dL0.0080.0013.117 \< 0.0011.0081.0061.011 AST U/L0.0000.00027.100 \< 0.0011.0001.0001.000 AST \> 37 U/L0.7760.11148.53 \< 0.0012.1731.7472.704 LDH U/L0.0000.0001.138 \< 0.0011.0001.0001.000 LDH \> 445 U/L0.7620.13133.978 \< 0.0012.1431.6582.768 Total bilirubin, mg/dL0.2540.03263.348 \< 0.0011.2891.2111.372 WBC, 109/mL0.0610.01034.632 \< 0.0011.0631.0411.084 Platelets, 1000/mL− 0.0040.00135.907 \< 0.0010.9960.9940.997 Platelets \> 138, 1000/mL0.9210.11959.427 \< 0.0012.5121.9873.175 INR0.2640.06019.253 \< 0.0011.3021.1571.465 PTT, sec0.0080.00214.361 \< 0.0011.0091.0041.013 Lactate, mmol/L0.0150.00417.724 \< 0.0011.0161.0081.023 Albumin, mg/dL− 0.0220.0132.9120.0880.9780.9541.003 Hemoglobin, g/dL− 0.1770.02647.489 \< 0.0010.8380.7970.881***Hemodynamic*** Heart rate, beats/min0.0070.0036.0450.0141.0071.0011.012 Heart rate \> 100 beats/min0.3520.1257.9060.0051.4231.1131.819 Diastolic BP, mmHg− 0.020.00518.695 \< 0.0010.9800.9720.989 Systolic BP, mmHg− 0.0060.0033.3610.0670.9940.9881.000 RA pressure, mmHg0.0620.00948.111 \< 0.0011.0641.0451.083 PCWP, mmHg0.0070.0071.0050.3161.0070.9941.020 PAP systolic− 0.0030.0030.8170.3660.9970.9911.003 PAP diastolic0.0020.0050.1320.7161.0020.9921.012 PAP mean, mmHg− 0.0010.0050.0530.8170.9990.9901.008 PAPi− 0.1260.02721.731 \< 0.0010.8820.8370.930 CO, L/min0.0750.0433.0130.0831.0780.9901.174 CI, L/min/m^2^0.1420.0793.2350.0721.1530.9871.346 RVSWI, g/m^2^/beat− 0.0630.01713.755 \< 0.0010.9390.9080.971 SVR, woods units− 0.0380.00821.820 \< 0.0010.9630.9480.978 PVR, woods units0.0330.0193.0650.0801.0330.9961.072 RA/PCWP0.6480.13921.753 \< 0.0011.9121.4562.511***Echocardiographic*** Severe RV dysfunction0.6000.13918.476 \< 0.0011.8211.3862.394 TAPSE, mm/s− 0.0110.0160.4990.4800.9890.9591.020 Moderate or severe tricuspid regurgitation0.2710.1076.4760.0111.3121.0641.616 Moderate or severe tricuspid regurgitation− 0.0300.1680.0320.8570.9700.6991.348 Moderate or severe mitral regurgitation0.2600.4040.4140.5201.2970.5872.863 Moderate or severe aortic regurgitation0.6860.20011.7320.0011.9861.3412.941 LV-EF grade \< 20%0.1520.1141.7640.1841.1640.9301.457***Operative and/or device variables*** Main LVAD strategy  BTT (on the list)40.523 \< 0.001Reference  BTC0.2860.1404.1730.0411.3311.0121.752  Destination therapy0.8060.15626.605 \< 0.0012.2381.6483.040  Rescue therapy1.0130.22121.008 \< 0.0012.7551.7864.248  BTR and others0.8430.3575.5850.0182.3241.1554.678 Surgical duration  Surgery time, min0.003050.574 \< 0.0011.0031.0021.004*AST* serum aspartate transaminase, *IABP* intra-aortic balloon pump, *INTERMACS* the Interagency Registry for Mechanically Assisted Circulatory Support (For INTERMACS classes. see text for details), *LV* left ventricular, *LVAD* left ventricular assist device, *VA-ECMO* veno-arterial extracorporeal membrane oxygenator, *NYHA* New York Heart Association, *PAP* pulmonary artery pressure, *PAPi* pulmonary artery pulsatility index, *PCWP* pulmonary capillary wedge pressure, *PVR* pulmonary vascular resistance, *RA* right atrial, *RV* right ventricular, *RVSWI* right-ventricular stroke work index, *TAPSE* tricuspid annular plane systolic excursion, *BTT* bridge to transplant, *BTC* bridge to candidacy, *BTR* bridge to recovery, *CPB* cardio pulmonary bypassTable 3Baseline multivariate predictors of early mortality after LVAD implantation using continuous valuesVariablesOR95.0% CI for OR*p* valueAge (years)1.0281.018--1.0380.000Gender (female)1.3391.003--1.7880.048INTERMACS Class 1--31.51.121--2.0070.006ECMO1.9891.431--2.7650.000Creatinine µmol/L1.0031.002--1.0050.000Total bilirubin g/dL1.1931.116--1.2750.000Lactate mmol/L1.0111.003--1.0190.008Hemoglobin g/dL0.9080.858--0.9610.001RA/PCWP1.741.292--2.3440.000PVR woods unit1.0891.044--1.1350.000SVR woods unit0.9740.957--0.9920.004Total implantation time (min)1.0031.002--1.0040.000For abbreviations, see Table [1](#Tab1){ref-type="table"}

ROC analysis of the two multivariable models yielded a predictive discriminative value of 0.75 (Fig. [3](#Fig3){ref-type="fig"}). Furthermore, the model had a good calibration by the Hosmer--Lemeshow statistic (Chi-square value, 8.38, *p* value: 0.40).Fig. 3Comparison of goodness of fit between the multivariable models using continuous versus categorical values. Receiver-operating characteristic curves showing similar area under the curve of the two models in predicting early (\< 90 day) death following LVAD implantation

Discussion {#Sec13}
==========

To the best of our knowledge, this is the first and largest study to explore differential causes of death in the early (90 days) post-LVAD in Europe. Earlier Intermacs annual reports described an early rapidly falling hazard phase merges with a constant phase at approximately 3 months \[[@CR22]\]. The main study findings are: (1) 18% of LVAD recipients died within 90 days following LVAD implantation; (2) MOF and sepsis followed by CPF and CVA are the most common causes of death in the early period; (5) A simple model of 12 variables predicted early mortality following LVAD implantation with a good discriminative power with area under the curve of 0.75.

Independent clinical predictors of early death were age, female sex, INTERMACS profile 1 to 3, and ECMO. Laboratory predictors included elevated serum creatinine, total bilirubin, lactate, and low hemoglobin. Furthermore, hemodynamic predictors included elevated RA-to-PCWP ratio, pulmonary vascular resistance, and low systemic vascular resistance. Longer total implantation time was also independent predictor of early mortality.

The common causes of death were MOF, CVA, and sepsis, followed by RHF and device malfunction in the early 90 days in the INTERMACS registry \[[@CR22]\]. Among the three mainstream LVAD brands used in this study, CVA has been shown more frequently in HVAD compared with HMII \[[@CR23]\]. Furthermore, the use of latest LVAD designs such as HM3 in the MOMENTUM 3 study was associated with less frequent thromboembolic complications than HMII \[[@CR24], [@CR25]\]. In our study of EUROMACS Registry, the main causes of early death were MOF (36%), sepsis (28%), cardiopulmonary failure (CPF; 10%), CVA (9%), and right-sided heart failure (RHF, 8%). Furthermore, MOF and sepsis are 70% of causes of death in the first week.

The cascade of RHF-induced cardiogenic shock, acute kidney failure, and MOF provokes high morbidity and mortality, including prolonged ICU stay and hospitalization. Congestion and/or ischemia of the gastrointestinal tract, particularly when associated with prolonged ICU stay, predisposes to bacterial translocation. In this study, 26% of deaths are due to sepsis with similar incidence in the early period following LVAD implantation. Infections are either VAD-specific, VAD-related, and/or non-VAD infections. Despite improved care, driveline infections are associated with high morbidity and mortality \[[@CR26]--[@CR28]\]. As abovementioned, prolonged ICU stay is associated with increased risk of infection consequently impacting survival post-LVAD \[[@CR14]\].

Components of predicting early mortality {#Sec14}
----------------------------------------

In our study, the predictors for early post-LVAD mortality are: older age, female sex, sicker, hospitalized patients (INTERMACS profile 1 to 3 and having ECMO), impaired renal and hepatic function (serum creatinine and total bilirubin), prolonged tissue hypoxia (lactate), and low hemoglobin. Furthermore, hemodynamic predictors included elevated RA-to-PCWP ratio, pulmonary vascular resistance, and low systemic vascular resistance reflecting right-sided heart failure. Prolonged total implantation time is associated with early mortality.

Our findings confirm also the role of advanced age and female sex as predictors of increased early mortality following LVAD implantation \[[@CR22], [@CR29]\].

High RA/PCWP is a sign of RHF, mostly in combination with volume overload. Aggressive pre- and post-operative diuresis for euvolemia, prolonged post-operative inotropic support, pulmonary vasodilators (e.g., nitric oxide, inhaled prostacyclin), and, in selected case, temporary RVAD support could help to prevent further complications of severe RHF. Furthermore, elevated PVR is associated with increased early death. High PVR contribute to RV afterload and decreased RV function. If the pulmonary artery compliance does not improve rapidly, post-LVAD risk of RHF increases \[[@CR14], [@CR21], [@CR30]\]. LVAD implantation will usually improve the RV function, the pulmonary and LV filling pressures. In the very, early post-operative phase, however, the RV needs time (probably \> 10--14 days) before physiological adaptation and recovery of the peri-operative hit of ischemia, distorted interventricular dependence, and volume overload will commence.

Our findings confirm that an advanced INTERMACS profile is associated with increased early mortality following LVAD implantation \[[@CR31]\]. Patients with advanced INTERMACS profile are sicker, have a higher incidence of biventricular failure, suffer from severe hemodynamic derangement with imminent secondary organ / multi-organ failure \[[@CR32]\]. However, in a recent trial, the early LVAD implantation in higher INTERMACS profiles (5--7) except for profile 4 failed to be superior to medical therapy, especially in terms of survival and quality of life \[[@CR33]\].

Patients presenting with acute "crush and burn" need stabilization with a temporary MCS before commencing to a durable MCS. However, currently available temporary MCS, such as VA-ECMO, Impella, and IABP, in patients in INTERMACS 1 results in poor outcome post-LVAD and, therefore, yet to be further explored \[[@CR16]\]. Furthermore, patients with pre-operative impaired renal and hepatic function, or prolonged peripheral tissue hypoxia (lactate) have increased early mortality following LVAD implantation. We believe that proper timing of LVAD, earlier in the process of end-stage heart failure, before a full-blown cardiogenic shock, is critical in achieving a good survival chance. Furthermore, appropriate and timely management of the right ventricular failure, prevention of severe kidney failure, and multi-organ failure are essential for a successful LVAD implantation.

Low hemoglobin level is associated with increased early mortality. Anemia is found in about one-third of chronic HF patients, most commonly due to anemia of chronic disease and chronic renal failure. Also, impaired nutrition, malabsorption due to congestion, abnormal production of hepcidin, and reduced intracellular uptake of iron have been reported as causes of anemia in patients with HF \[[@CR34], [@CR35]\]. Therefore, anemia might reflect the severity of the illness pre-LVAD.

Finally, prolonged time of LVAD surgery is associated with increased early mortality following LVAD implantation. This finding has been also shown in previous study by our group in which prolonged surgery time is associated with increased early right-sided heart failure complicating an ICU course \[[@CR14]\].

Clinical implications {#Sec15}
---------------------

We found that the most common causes of death early post-LVAD are MOF, sepsis, and CPF. Patients dying early after LVAD implantation were older, often female, sicker (INTERMACS profile 1--3), suffering from pre-operative anemia, impaired renal and liver function, and having signs of impending or evident RHF. Those patients with high RA/PCWP have probably already compromised RV function and higher risk of post-operative right-sided heart failure. It is known that half of ICU patients had a nosocomial infection and are, therefore, at a high risk for sepsis \[[@CR36]\]. Furthermore, as abovementioned, congested gut has been identified as a source of infection and is a known sepsis triggering problem in ICU patients with MOF, due to translocation of gut flora into the bloodstream \[[@CR36], [@CR37]\].

Based on the two main causes of death in early post-LVAD, MOF, and sepsis, we should encourage clinicians to prevent deterioration of the RV function. A tailored risk-based approach focused on prevention and timely management of pre- and post-operative RHF via pharmacological and/or temporary RVAD. A patient with a high risk for early mortality may benefit from early or prophylactically short-term mechanical circulatory support, and above all aggressive pre- and post-operative optimization of the right-sided fillings pressures. Second, early decision of LVAD implantation could select patients with less sicker patients, increasing INTERMACS profile and risk of secondary organ failure.

Limitations {#Sec16}
===========

There are several limitations that should be acknowledged in this study including the retrospective analysis. Multi-national, multicenter registry like EUROMACS Registry without yet formal financial and manpower reimbursement from the national health authorities, insurance, the incomplete, has inherent shortcomings, like missing data. Several parameters were incompletely collected in the database. Therefore, we used multiple imputations to account for randomly missing data. However, this approach is based on strong assumptions that it is not possible to verify.

An another important limitation was also the retrospective analysis of the EUROMACS database. Another important limitation was the clinical judgment of the primary cause of death by which in case of multi-organ failure or sepsis was based on clinician's own decision per site. Similarly, cardiopulmonary failure, which contains left heart failure, lung failure, pulmonary artery embolization, and myocardial infarction, could be used in different way from the centers with underspecifying diseases like acute respiratory distress syndrome (ARDS) as lung failure. Furthermore, without a central core laboratory analysis of the imaging data, it is presumptuous that all data are analyzed in accordance with the published guidelines. However, the site initiation/audit and the protocol of the EUROMACS registry require that the site investigators to perform their analysis according to the published guidelines.

Conclusions {#Sec17}
===========

In the European Registry for Patients with Mechanical Circulatory Support, approximately one out of five patients died within 90 days following LVAD implantation. Early mortality is primarily dominated by multiorgan failure followed by sepsis. A simple model comprises 12 variables predicts early mortality following LVAD implantation with a good discriminative power of an area under the curve of 0.75.
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APTT

:   Activated partial thromboplastin time

BTC

:   Bridge to candidacy

BTT

:   Bridge to transplant

CI

:   Confidence interval

CVA

:   Cerebro-vascular accident

DT

:   Destination therapy

ECMO

:   Extracorporeal membrane oxygenation

EUROMACS

:   The European Registry for Patients with Mechanical Circulatory Support

IABP

:   Intra-aortic balloon pump

ICU

:   Intensive-care unit

INTERMACS

:   The Interagency Registry for Mechanically Assisted Circulatory Support

LV

:   Left ventricle/ventricular

LVAD

:   Left ventricular assist device

MOF

:   Multiorgan failure

HR

:   Hazard ratio

RHF

:   Right-sided heart failure

RV

:   Right ventricle/ventricular
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